Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.63 |
| ▸ | SKP1 | P63208 | 2/20 | 0.63 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.63 |
| ▸ | HTR3A | P46098 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | CCKAR | P32238 | 2/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.48 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31254501 | 1.00 | CKS1B (0.63) | CKS1BSKP1SKP2HTR3AGPR119 | |
| SCHEMBL31254495 | 0.95 | CKS1B (0.66) | CKS1BSKP1SKP2HTR3AGPR119 | |
| SCHEMBL29809787 | 0.81 | CKS1B (0.53) | CKS1BSKP1SKP2GPR119MAP4K4 | |
| SCHEMBL22576378 | 0.81 | CKS1B (0.53) | CKS1BSKP1SKP2GPR119MAP4K4 | |
| SCHEMBL30501971 | 0.81 | CKS1B (0.53) | CKS1BSKP1SKP2GPR119MAP4K4 | |
| SCHEMBL24469178 | 0.81 | CKS1B (0.53) | CKS1BSKP1SKP2GPR119MAP4K4 | |
| SCHEMBL4063357 | 0.80 | CKS1B (0.69) | CKS1BSKP1SKP2HTR3AGPR119 | |
| SCHEMBL5236678 | 0.80 | HTR3A (0.63) | CKS1BSKP1SKP2HTR3ACCKAR | |
| SCHEMBL461584 | 0.80 | CKS1B (0.62) | CKS1BSKP1SKP2GPR119MAP4K4 | |
| SCHEMBL18163269 | 0.80 | MAP4K4 (0.54) | CKS1BSKP1SKP2GPR119MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260441-B2 | Heteroaryl compounds with cyclic bridging unit | INTERVET INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150080365-A1 | HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT | INTERVET INC. | 2015-03-19 | — | — | US | disclosed |
| EP-2830615-A1 | HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR USE IN THE TREATMENT HELMINTH INFECTION | Intervet International B.V. (NL) | 2015-02-04 | — | — | EP | disclosed |
| EP-2778155-A1 | 2-aminopyridine derivatives useful as kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110077237-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| EP-2121613-A2 | 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| WO-2008094992-A2 | 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | CKS1B 137/4885SKP1 386/4885SKP2 219/4885 |
| US-20120214799-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | CKS1B 137/4885SKP1 386/4885SKP2 219/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | CKS1B 137/4885SKP1 386/4885SKP2 219/4885 |
| US-20150080365-A1 | HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT | PIGS, MTCL3, GJB2 | CKS1B 3269/4885SKP1 4265/4885SKP2 3328/4885 |
| US-20110077237-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | CKS1B 137/4885SKP1 386/4885SKP2 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.